Back to top
more

Myriad Genetics (MYGN)

(Real Time Quote from BATS)

$5.56 USD

5.56
11,488,990

+1.69 (43.67%)

Updated Aug 6, 2025 02:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Reasons to Hold on to Myriad Genetics (MYGN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN) owing to strong Q1 2022 results and growth in testing volumes.

Zacks Equity Research

Myriad Genetics (MYGN) Reports Loss in Q1, Gross Margin Down

by Zacks Equity Research

Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.

Zacks Equity Research

Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -4.41% and 12.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myriad Genetics (MYGN) Makes Progress in Precision Oncology

by Zacks Equity Research

Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.

Zacks Equity Research

Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.

Zacks Equity Research

Myriad Genetics (MYGN) to Offer Companion Diagnostic for Lynparza

by Zacks Equity Research

Myriad Genetics' (MYGN) BRACAnalysis CDx gained FDA nod for identifying breast cancer patients eligible for treatment with Lynparza.

Zacks Equity Research

Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.

Zacks Equity Research

Myriad Genetics (MYGN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 1.64% and 11.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myriad Genetics (MYGN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.

Zacks Equity Research

Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.

Zacks Equity Research

Myriad Genetics (MYGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of -300.00% and 1.80%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain LabCorp (LH) Stock For Now

by Zacks Equity Research

Strength in Drug Development business and new strategies to expand into high-growth markets raise optimism for LabCorp (LH).

Zacks Equity Research

Here's Why You Should Retain Myriad Genetics (MYGN) for Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN) owing to strong testing volume growth and notable product launches.

Zacks Equity Research

LabCorp (LH) Gets FDA's EUA for Combined Home Collection Kit

by Zacks Equity Research

The EUA for LabCorp's (LH) combined home collection kit can enable health-care providers to identify and treat individuals suspected of COVID-19 or influenza A/B infection.

Zacks Equity Research

LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra

by Zacks Equity Research

According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.

Zacks Equity Research

Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal

by Zacks Equity Research

Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.

Zacks Equity Research

Agilent (A) Boosts PD-L1 IHC 22C3 pharmDX Assay Use in Europe

by Zacks Equity Research

Agilent Technologies (A) boosts presence in the companion diagnostics market by expanding the use of PD-L1 IHC 22C3 pharmDx assay for esophageal cancer treatment in Europe.

Zacks Equity Research

Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.

Zacks Equity Research

Myriad Genetics (MYGN) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 271.43% and 13.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core Units

by Zacks Equity Research

Myriad Genetics' (MYGN) new divesture will enable company to accelerate the execution of transformation plan and drive growth.

Zacks Equity Research

Why Is Myriad (MYGN) Down 11.5% Since Last Earnings Report?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Myriad Genetics (MYGN) Sells myPath to Focus on Core Units

by Zacks Equity Research

Myriad Genetics' (MYGN) new divesture will provide the company with growth capital for future investments.